Department of Neurology

Training Sites


Parkinson's Disease Center and Movement Disorders Clinic


Located in the Texas Medical Center, the Parkinson’s Disease Center and Movement Disorders Clinic occupies a section of the 9th floor of the McNair Building.

This includes three academic offices for each of the full-time PDCMDC faculty, two offices for four fellows, one office for research nurse manager, one office for database manager, one conference room (which is contiguous with a video lab), the Experimental Therapeutics Center (five examining rooms, and two offices for clinical research coordinators), a room for programming of Deep Brain Stimulators (DBS), and an administrative area for four secretaries and additional space for equipment and storage. In addition, the PDCMDC utilizes nine examining rooms and nursing station with two medical assistants.

The PDCMDC also shares a large conference room with state-of-the art audio-visual equipment for weekly video rounds and genetic conferences, and monthly research, DBS, staff and other meetings.

The PDCMDC is actively involved in patient care, research, education and other academic and scholarly activities. Drawing from a large referral population, the PDCMDC is one of the most productive clinical and research movement disorders centers in the world. The clinic's 12,000 patient visits per year and a database of more than 30,000 patients provide a powerful research resource for effective recruitment into various clinical trials and other clinical research projects. The PDCMDC conducted the first double-blind, placebo-controlled trial of botulinum toxin in the treatment of cranial-cervical dystonia and the findings from the study led to the initial approval of botulinum toxin by the Food and Drug Administration (FDA) in 1989.

Since 1981, the PDCMDC has treated more than 8,000 patients with botulinum toxin. Dr. Jankovic was granted Investigational Exemption for a New Drug (IND) in 1979 and since that time the researchers at the PDCMDC have conducted dozens of clinical trial with tetrabenazine, a monoamine depleter. The drug was approved by the FDA in 2008 as the first treatment for chorea associated with Huntington's disease. Since 1995 the PDCMDC has collected 3,871 DNA samples, stored in a DNA repository. The PDCMDC DBS database has maintained records on 720 patients since 1983. The National Parkinson Foundation recognized the accomplishments of the PDCMDC by selecting it as one of its first Centers of Excellence and by supporting the center since 1992. In 2001, the Huntington’s Disease Society of America also awarded the PDCMDC the status of a Center of Excellence. Since its foundation, the researchers at the PDCMDC have conducted hundreds of clinical trials and published over one thousand scientific articles.